Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
VBI Vaccines
VBI Vaccines
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Regulatory
VBI Vaccines receives positive EMA Scientific Advice regarding Sci-B-Vac Phase III clinical Study
VBI Vaccines Inc. has received positive Scientific Advice for its Sci-B-Vac vaccine in Europe
Research & Development
VBI Vaccines appoints Dr Francisco Diaz-Mitoma as Chief Medical Officer
He will oversee clinical development initiatives at the firm
Research & Development
VBI Vaccines applies its eVLP platform to development of Zika vaccine
The eVLP platform enables the development of vaccines that mimic the structure of viruses found in nature
Research & Development
Sanofi Pasteur to use VBI technology to develop more stable vaccine candidate
French company has the option to acquire certain worldwide rights to LPV technology
Subscribe now